Comparative pharmacokinetics and pharmacodynamics of eterobarbital and phenobarbital in normal volunteers

N. Barzaghi, G. Gatti, R. Manni, C. A. Galimberti, C. Zucca, E. Perucca, A. Tartara

Research output: Contribution to journalArticlepeer-review

Abstract

The comparative pharmacokinetics and pharmacodynamics of single oral doses of eterobarbital (N, N′-dimethoxymethylphenobarbital, DMMP, 400 mg) and phenobarbital (200 mg) were evaluated in a double-blind study in 8 normal volunteers. Following administration of DMMP, no unchanged drug could be detected in serum. The active monomethoxymethyl metabolite (MMP) appeared rapidly in the circulation but its concentration remained generally low and declined below the limit of detection (0.5 μg/ml) usually before 9.5 h. Serum levels of DMMP-derived PB increased slowly and reached a peak between 24 and 48 h in most cases. One subject showed an atypical pharmacokinetic profile, characterized by relatively high levels of MMP and a delayed appearance of low levels of PB. After administration of PB, serum drug levels peaked within 1.5 h and remained, at all sampling times, higher than those observed after intake of DMMP. Compared with DMMP, PB induced greater sedative effects as assessed by visual analogue rating scale, critical flicker fusion frequency and multiple sleep latency tests.

Original languageEnglish
Pages (from-to)81-87
Number of pages7
JournalEuropean Journal of Drug Metabolism and Pharmacokinetics
Volume16
Issue number1
DOIs
Publication statusPublished - Jan 1991

Keywords

  • eterobarbital
  • man
  • Multiple Sleep Latency Tests (MSLTs)
  • pharmacodynamics
  • pharmacokinetics
  • Phenobarbital

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Fingerprint Dive into the research topics of 'Comparative pharmacokinetics and pharmacodynamics of eterobarbital and phenobarbital in normal volunteers'. Together they form a unique fingerprint.

Cite this